Neurol. praxi. 2014;15(1):31-35
Treatment of multiple sclerosis in Czech Republic - options and reality
- I. neurologická klinika MU, FN u sv. Anny v Brně
Treatment options in multiple sclerosis have expanded considerably in the recent years. In 2013, several new effective drugs were registered and more will be introduced in therapeutic practice in the coming years. However, the availability of drugs is limited due to restrictions of health care payers. Reimbursement regulations are often in conflict with evidence-based medicine. This article deals with both the good prospects in treating multiple sclerosis including an overview of new drugs and the current situation in the Czech Republic. The article presents specific cases of discrepancy between therapeutic options and the clinical reality.
Keywords: multiple sclerosis, clinically isolated syndrome, interferon beta, glatiramer acetate, natalizumab, fingolimod, indication restrictions
Published: March 1, 2014 Show citation
References
- Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R; MN166-001 Investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010; 74(13): 1033-1040.
Go to original source... 
Go to PubMed... - Beck RW, Cleary PA, Anderson MM, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, Savino PJ, Guy JR, Trobe JD, McCrary JA, Smith CH, Chrousos GA, Thompson HS, Katz BJ, Brodsky MC, Goodwin JA and the Optic Neuritis Study Group. A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis. N Engl J Med 1992; 326: 581-588. Go to original source... Go to PubMed...
- Beck RW, Cleary PA. Optic Neuritis Treatment Trial, One-Year Follow-up Results Arch Ophthalmol. 1993; 111(6): 773-775. Go to original source... Go to PubMed...
- Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856): 1829-1839. Go to original source... Go to PubMed...
- Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, Hartung HP, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR, and the Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582. Go to original source... Go to PubMed...
- Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374(9700): 1503-1511. Go to original source... Go to PubMed...
- Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012; 11(1): 33-41. Go to original source... Go to PubMed...
- Havrdová E., Piťha J. Národní sada klinických standardů. 31. Klinický standard pro diagnostiku a léčbu roztroušené sklerózy a neuromyelitis optica. Březen 2012. http://www.czech-neuro.cz/data/q/O/V/0031-rs-odborna.pdf.
- Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Start WH, van den Noort S. Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: Subcommittee of the American. Multiple Sclerosis Therapy Consensus Group (2004). Escalating immunotherapy of multiple sclerosis. J Neurol. 251: 1329-1339.
- Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000 Sep 28; 343(13): 898-904. Go to original source... Go to PubMed...
- Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R; for the BENEFIT Study Group. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249. Go to original source... Go to PubMed...
- McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1): 121-127. Go to original source... Go to PubMed...
- Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the, ,McDonald Criteria". Ann Neurol. 2005; 58 (6): 840-846. Go to original source... Go to PubMed...
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald kriteria. Ann Neurol. 2011; 69(2): 292-302. Go to original source... Go to PubMed...
- Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, Selmaj K, Visser LH, S?rensen PS. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses Journal of Neurology 2005; 12: 939-946. Go to original source... Go to PubMed...